Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | Director | June 29, 2026 | June 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HALOZYME THERAPEUTICS, INC.
Report date June 29, 2026 · Filed June 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,462 |
Ending reported balance
After 2026-06-29 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-29 · Exercise / conversion · Acquired 7,304 · Balance 21,766 Row 2 · 2026-06-29 · Sale · Disposed 7,304 · Balance 14,462 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 19, 2026 in accordance with Rule 10b5-1. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $38.46 · Expires 2034-04-25 | Direct | 1,500 |
Reported balance
After 2026-06-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-29 · Exercise / conversion · Disposed 7,304 · Balance 1,500 F2: Grant to Reporting Person of options exercisable as of April 25, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 19, 2026 in accordance with Rule 10b5-1.
F2: Grant to Reporting Person of options exercisable as of April 25, 2025.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CHINOOK THERAPEUTICS, INC.
Report date August 11, 2023 · Filed August 11, 2023
Section 16 reporting ended · disclosed 2023-08-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 1
1 source rowRow 1 · 2023-08-11 · Disposition to issuer · Disposed 1,275 · Balance 0 F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.74 · Expires 2032-04-01 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-08-11 · Disposition to issuer · Disposed 26,600 · Balance 0 F2: This stock option award, which provided for ratable vesting in 36 monthly installments beginning on May 2, 2022, became fully vested and was canceled upon effectiveness of the Merger , and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-08-11 · Disposition to issuer · Disposed 4,401 · Balance 0 F3: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F4: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on April 2, 2023. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger.
F2: This stock option award, which provided for ratable vesting in 36 monthly installments beginning on May 2, 2022, became fully vested and was canceled upon effectiveness of the Merger , and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F3: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement.
F4: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on April 2, 2023. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 29, 2026 Filed Jun 30, 2026 21:25 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 7,304 | $0.00 Strike: $38.46 | $0.00 |
DisclosureSEC source: 0001159036-26-000082 · wk-form4_1782854707.xml · derivative · entry 3 Krishnan Mahesh · CIK 0001866746 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 7,304 shares Expires 2034-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Grant to Reporting Person of options exercisable as of April 25, 2025. Read SEC document |
| June 29, 2026 Filed Jun 30, 2026 21:25 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 7,304 | $75.00 | $547,800.00 |
DisclosureSEC source: 0001159036-26-000082 · wk-form4_1782854707.xml · nonDerivative · entry 2 Krishnan Mahesh · CIK 0001866746 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,462 F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 19, 2026 in accordance with Rule 10b5-1. Read SEC document |
| June 29, 2026 Filed Jun 30, 2026 21:25 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 7,304 | $38.46 | $280,911.84 |
DisclosureSEC source: 0001159036-26-000082 · wk-form4_1782854707.xml · nonDerivative · entry 1 Krishnan Mahesh · CIK 0001866746 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,766 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2026 Filed May 7, 2026 23:04 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 6,040 | $0.00 Strike: $65.87 | $0.00 |
DisclosureSEC source: 0001159036-26-000063 · wk-form4_1778195038.xml · derivative · entry 2 Krishnan Mahesh · CIK 0001866746 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,040 Underlying: Common Stock · 6,040 shares Expires 2036-05-05 F2 · derivative.exercise_date: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 05, 2026 Filed May 7, 2026 23:04 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 3,796 | $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000063 · wk-form4_1778195038.xml · nonDerivative · entry 1 Krishnan Mahesh · CIK 0001866746 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,462 F1 · shares: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 01, 2025 Filed May 2, 2025 20:08 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 5,750 | $0.00 Strike: $60.03 | $0.00 |
DisclosureSEC source: 0001415889-25-011773 · form4-05022025_080502.xml · derivative · entry 2 Krishnan Mahesh · CIK 0001866746 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,750 Underlying: Common Stock · 5,750 shares Expires 2035-05-01 F2 · derivative.exercise_date: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 1, 2026 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 01, 2025 Filed May 2, 2025 20:08 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 4,165 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011773 · form4-05022025_080502.xml · nonDerivative · entry 1 Krishnan Mahesh · CIK 0001866746 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,666 F1 · shares: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 1, 2026 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| April 25, 2024 Filed Apr 29, 2024 22:01 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 8,804 | $0.00 Strike: $38.46 | $0.00 |
DisclosureSEC source: 0001415889-24-011692 · form4-04292024_100456.xml · derivative · entry 2 Krishnan Mahesh · CIK 0001866746 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,804 Underlying: Common Stock · 8,804 shares Expires 2034-04-25 F2 · derivative.exercise_date: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| April 25, 2024 Filed Apr 29, 2024 22:01 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 6,501 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-011692 · form4-04292024_100456.xml · nonDerivative · entry 1 Krishnan Mahesh · CIK 0001866746 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,501 F1 · shares: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:10 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerRestricted Stock Units · Derivative | 4,401 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-045428 · doc4.xml · derivative · entry 3 Krishnan Mahesh · CIK 0001866746 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,401 shares Expires not disclosed F3 · derivative.exercise_price: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F4 · price: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on April 2, 2023. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. F4 · derivative.exercise_date: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on April 2, 2023. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. F4 · derivative.expiration_date: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on April 2, 2023. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:10 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerStock Option (Right to Buy) · Derivative | 26,600 | $23.26 Strike: $16.74 | $618,716.00 |
DisclosureSEC source: 0001209191-23-045428 · doc4.xml · derivative · entry 2 Krishnan Mahesh · CIK 0001866746 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,600 shares Expires 2032-04-01 F2 · derivative.exercise_date: This stock option award, which provided for ratable vesting in 36 monthly installments beginning on May 2, 2022, became fully vested and was canceled upon effectiveness of the Merger , and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:10 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerCommon Stock | 1,275 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-045428 · doc4.xml · nonDerivative · entry 1 Krishnan Mahesh · CIK 0001866746 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger. Read SEC document |
| April 04, 2023 Filed Apr 4, 2023 21:14 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | SaleCommon Stock | 924 | $23.01 | $21,261.24 |
DisclosureSEC source: 0001209191-23-023108 · doc4.xml · nonDerivative · entry 2 Krishnan Mahesh · CIK 0001866746 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,275 F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person dated February 10, 2023. Read SEC document |
| April 01, 2023 Filed Apr 4, 2023 21:14 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionRestricted Stock Units · Derivative | 2,199 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023108 · doc4.xml · derivative · entry 3 Krishnan Mahesh · CIK 0001866746 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,401 Underlying: Common Stock · 2,199 shares Expires 2025-04-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on April 1, 2023, until fully vested subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 01, 2023 Filed Apr 4, 2023 21:14 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionCommon Stock | 2,199 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-023108 · doc4.xml · nonDerivative · entry 1 Krishnan Mahesh · CIK 0001866746 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| April 02, 2022 Filed Apr 5, 2022 18:47 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | GrantRestricted Stock (RSU)(Common Stock) · Derivative | 6,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-023291 · doc4.xml · derivative · entry 2 Krishnan Mahesh · CIK 0001866746 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,600 Underlying: Common Stock · 6,600 shares Expires 2025-04-02 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on April 2, 2023, until fully vested subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 02, 2022 Filed Apr 5, 2022 18:47 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | GrantStock Option (right to buy) · Derivative | 26,600 | $0.00 Strike: $16.74 | $0.00 |
DisclosureSEC source: 0001209191-22-023291 · doc4.xml · derivative · entry 1 Krishnan Mahesh · CIK 0001866746 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,600 Underlying: Common Stock · 26,600 shares Expires 2032-04-01 F1 · derivative.exercise_date: The stock option fully vests as to 1/36 of the total shares monthly beginning on May 2, 2022 until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.